Polyneuropathies is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Polyneuropathies have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Polyneuropathies compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Polyneuropathies overview
Polyneuropathies represent a group of disorders characterized by damage or dysfunction affecting multiple peripheral nerves, often leading to sensory, motor, and autonomic nerve impairments. These conditions can result from various causes, including diabetes, infections, autoimmune diseases, metabolic disorders, or exposure to toxins. Symptoms range from tingling, numbness, and muscle weakness to pain, difficulties in coordination, and impaired organ function. Diagnosis involves comprehensive medical history, physical examinations, nerve conduction studies, and sometimes imaging or laboratory tests. Treatment focuses on addressing the underlying cause, managing symptoms, and may include medications, physical therapy, and lifestyle adjustments, aiming to alleviate discomfort and improve functionality based on the specific condition and its severity.
For a complete picture of PTSR and LoA scores for drugs in Polyneuropathies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
